Huahai Pharmaceuticals: Received the registration certificate for Carvedilol Sodium Injection.

Huali Pharmaceuticals announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approved and issued injection solution of Carotene Sodium. The Carotene Sodium injection solution is mainly used for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology and obstetrics. The estimated sales amount in the domestic market in 2024 is about 250 million yuan. The company has invested approximately 7.12 million yuan in research and development expenses for this project. This approval will enrich the company's product line and enhance market competitiveness.